Authors

Laura M. Kulik, MD, Northwestern University Feinberg School of Medicine

Latest:

Informed Patients Are More Likely to Choose Palliative Care

Research from Tulane University provides a strong case that, across demographic and clinical populations, informed patients are less wary of palliative care and more inclined to take advantage of the favorable effects that palliative care services can offer for patient-centered outcomes.

Laura Metcalfe, MSN, RN

Latest:

Laura Metcalfe on Colorectal Screening

Laura Metcalfe, MSN, RN, APN, C, AOCNS Advanced Practice Nurse, GI Division from John Theurer Cancer Center on Colorectal Screening

Laura Michaelis, MD

Latest:

Dr. Michaelis Discusses the JAK2 Mutation in MPNs

Laura Michaelis, MD, associate professor of medicine, Medical College of Wisconsin, discusses implications for the JAK2 mutation in patients with myeloproliferative neoplasms.

Laura Panjwani

Latest:

Expert Discusses Promise of Quizartinib in AML

Mark Levis, MD, PhD, highlights the promise and potential challenges of the FLT3-inhibitor quizartinib in acute myeloid leukemia.

Laura Quan Man Chow, MD, FRCPC

Latest:

Dr. Chow on the Use of Ceritinib in ALK+ NSCLC Metastatic to the Brain

Laura Quan Man Chow, MD, FRCPC, discusses the use of ceritinib (Zykadia) in patients with ALK-positive non–small cell lung cancer that has metastasized to the brain.

Laura Spring, MD

Massachusetts General Hospital

Latest:

Sequencing Antibody-Drug Conjugates (ADCs) in HR+/HER2-Low Metastatic Breast Cancer

Laura Spring, MD, and Manali Bhave, MD, discuss sequencing approved antibody-drug conjugates, T-DM1 and sacituzumab govitecan, for hormone receptor-positive, HER2-low metastatic breast cancer after progression on chemotherapy.

Laura van 't Veer, PhD

Latest:

Dr. van 't Veer on Guidelines for Genetic Testing in Breast Cancer

Laura van ’t Veer, PhD, Leader of the Breast Oncology Program, and director of Applied Genomics, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the guidelines for genetic testing in breast cancer.

Laura W. Goff, MD

Latest:

Other Clinical Trials With Chemoimmunotherapy in Biliary Tract Cancers

Expert perspectives on the KEYNOTE-966 and IMbrave151 clinical trials and novel chemoimmunotherapy combination strategies in biliary tract cancers.

Laura Yarbro, PharmD

Latest:

Denosumab: A Review of Its Pharmacology and Clinical Implications

It is estimated that approximately 80% of all patients with diagnoses of breast cancer, prostate cancer, or multiple myeloma will develop bone metastases at some time during the course of their disease.

Laurel A. Menapace, MD

Latest:

Challenging Case Teaches Oncology Fellow the Power of Hope

Advanced esophageal cancer is a highly lethal malignancy and often spreads despite aggressive therapy.

Laurel W. Rice, MD

Latest:

Dr. Rice on the Importance of Clinical Trials in Gynecologic Cancer

Laurel W. Rice, MD, chair, Department of Obstetrics and Gynecology, University of Wisconsin School of Medicine and Public Health, discusses the importance of enrolling patients with gynecologic cancer on clinical trials.

Lauren C. Harshman, MD

Latest:

New Perioperative Strategies Emerge for High-Risk, Resectable RCC

The current management of metastatic renal cell carcinoma reflects the progress of medical oncology throughout the past several decades. The standard of care has evolved from cytokine-based therapies to targeted molecular therapies and immune checkpoint inhibitor–based strategies.

Lauren C. Harshman, MD1

Latest:

The Therapeutic Landscape of Metastatic Renal Cell Carcinoma in 2012

In the last seven years, since the introduction of the targeted therapies, remarkable progress has transpired that has transformed the therapeutic landscape for metastatic renal cell carcinoma.

Lauren C. Pinter-Brown, MD,

Latest:

CTCL Today: Remaining Unmet Needs in CTCL

Panelists discuss how unmet needs in cutaneous T-cell lymphoma include the lack of a cure, the need for better biomarkers for early diagnosis and treatment response prediction; improving patients' quality of life by managing symptoms, such as itch; advancing understanding of disease biology to develop effective targeted therapies, such as cell therapy; and the importance of multidisciplinary care and clinical trial participation.

Lauren C. Pinter-Brown, MD, UCI Health

Lauren C. Pinter-Brown, MD, UCLA

Lauren Carcas, MD

Latest:

Dr. Carcas on the Design and Findings of CONTROL Trial in HER2+ Breast Cancer

Lauren Carcas, MD, medical oncologist, Miami Cancer Institute, Baptist Health South Florida, discusses the design of the CONTROL trial and her personal experience with prophylaxis interventions for women with early-stage HER2-positive breast cancer receiving neratinib (Nerlynx).

Lauren Ettlinger

Lauren Green

Latest:

Web-Based Exercises Effective in Improving Cognitive Impairment Following Chemotherapy

Patients with symptoms of cognitive impairment who practiced web-based memory and mental processing exercises over a period of 15 weeks experienced marked improvement in their cognitive function.